Literature DB >> 32449042

Culture-negative periprosthetic joint infection: prevalence, aetiology, evaluation, recommendations, and treatment.

Irene Kalbian1, Jung Wee Park2, Karan Goswami1, Young-Kyun Lee3, Javad Parvizi1, Kyung-Hoi Koo4.   

Abstract

PURPOSE: Periprosthetic joint infection (PJI) is a catastrophic complication after total joint arthroplasty (TJA). Treatment of PJI is challenging, especially when causative microorganism is not identified. The purpose of this systematic review was to guide diagnostic approach and treatment of culture-negative (CN) PJI.
METHODS: A systematic review was undertaken on clinical studies from MEDLINE, EMBASE, Cochrane Library, and Scopus databases. Basic science studies, letters, studies written in languages other than English, case reports, and review articles were excluded.
RESULTS: Proportion of CN PJI ranged from 5 to 42% of PJIs. Risk factors for culture negativity included prior use of antibiotic before culture test, inappropriate culture tools, insufficient culture period, and post-operative wound drainage. Specific diagnostic protocols including repeating sampling, longer incubation period, culture in blood culture bottles, sonication of implants, polymerase chain reaction in synovial fluid, and next-generation sequencing are recommended to identify undetected microorganisms. Vancomycin and cephalosporins are the most commonly used antibiotics. Two-stage revision arthroplasty showed success rate of 70-100%.
CONCLUSIONS: A comprehensive review was performed to provide an up-to-date, evidence-based guide to the management of CN PJI.

Entities:  

Keywords:  Arthroplasty; Culture; Infection; Systematic review

Mesh:

Substances:

Year:  2020        PMID: 32449042     DOI: 10.1007/s00264-020-04627-5

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  7 in total

Review 1.  Diagnostic Value of Next-Generation Sequencing in Periprosthetic Joint Infection: A Systematic Review.

Authors:  Yuchen Tang; Dacheng Zhao; Shenghong Wang; Qiong Yi; Yayi Xia; Bin Geng
Journal:  Orthop Surg       Date:  2021-12-21       Impact factor: 2.071

2.  The DendrisCHIP® Technology as a New, Rapid and Reliable Molecular Method for the Diagnosis of Osteoarticular Infections.

Authors:  Elodie Bernard; Thomas Peyret; Mathilde Plinet; Yohan Contie; Thomas Cazaudarré; Yannick Rouquet; Matthieu Bernier; Stéphanie Pesant; Richard Fabre; Aurore Anton; Cathy Maugis-Rabusseau; Jean Marie François
Journal:  Diagnostics (Basel)       Date:  2022-05-30

3.  Tolerant Small-colony Variants Form Prior to Resistance Within a Staphylococcus aureus Biofilm Based on Antibiotic Selective Pressure.

Authors:  Robert Manasherob; Jake A Mooney; David W Lowenberg; Paul L Bollyky; Derek F Amanatullah
Journal:  Clin Orthop Relat Res       Date:  2021-07-01       Impact factor: 4.755

Review 4.  An update about molecular biology techniques to detect orthopaedic implant-related infections.

Authors:  Jaime Esteban; Enrique Gómez-Barrena
Journal:  EFORT Open Rev       Date:  2021-02-01

5.  Globulin and albumin to globulin ratio precisely diagnose periprosthetic joint infection and determine the timing of second-stage reimplantation.

Authors:  Guangqian Shang; ZhiXuan Fei; Hao Xu; Yingzhen Wang; Shuai Xiang
Journal:  J Orthop Surg Res       Date:  2022-01-06       Impact factor: 2.359

6.  Microbiology of hip and knee periprosthetic joint infections: a database study.

Authors:  Don Bambino Geno Tai; Robin Patel; Matthew P Abdel; Elie F Berbari; Aaron J Tande
Journal:  Clin Microbiol Infect       Date:  2021-06-12       Impact factor: 8.067

7.  Development and validation of case-finding algorithms to identify prosthetic joint infections after total knee arthroplasty in Veterans Health Administration data.

Authors:  Erica J Weinstein; Alisa Stephens-Shields; Bogadi Loabile; Tiffany Yuh; Randi Silibovsky; Charles L Nelson; Judith A O'Donnell; Evelyn Hsieh; Jennifer S Hanberg; Kathleen M Akgün; Janet P Tate; Vincent Lo Re
Journal:  Pharmacoepidemiol Drug Saf       Date:  2021-07-05       Impact factor: 2.732

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.